Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 7, 2015; 21(29): 8811-8816
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811
Table 1 Randomized phase III trials in the second-line treatment of gastric cancer
| Trials | Treatment | No. of patients | OS (mo) | HR for OS(95%CI) | Remarks |
| AIO[8] | Irinotecan | 21 | 4.0 | 0.48 (0.25-0.92) | Closed early due to poor accrual |
| BSC | 19 | 2.4 | P = 0.012 | ||
| Korean[9] | Docetaxel or irinotecan | 133 | 5.3 | 0.657 (0.485-0.891) | No OS difference between docetaxel (5.5 mo) and irinotecan (6.5 mo) |
| BSC | 69 | 3.8 | P = 0.007 | ||
| COUGAR-02[10] | Docetaxel | 84 | 5.2 | 0.67 (0.49-0.92) | Global QOL similar between arms (P = 0.53) |
| BSC | 84 | 3.6 | P = 0.01 | ||
| REGARD[11] | Ramucirumab | 238 | 5.2 | 0.776 (0.603-0.998) | |
| Placebo | 117 | 3.8 | P = 0.047 | ||
| RAINBOW[12] | Ramucirumab + paclitaxel | 330 | 9.6 | 0.807 (0.678-0.962) | |
| Placebo + paclitaxel | 335 | 7.4 | P = 0.017 | ||
| WJOG 4007[15] | Paclitaxel | 108 | 9.5 | 1.14 (0.88-1.49) | |
| Irinotecan | 111 | 8.4 | P = 0.24 |
- Citation: Kim SM, Park SH. Chemotherapy beyond second-line in advanced gastric cancer. World J Gastroenterol 2015; 21(29): 8811-8816
- URL: https://www.wjgnet.com/1007-9327/full/v21/i29/8811.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i29.8811